Rxrx stock forecast.

Find the latest Recursion Pharmaceuticals, Inc. (RXRX) stock quote, history, news and other vital information to help you with your stock trading and investing.

Rxrx stock forecast. Things To Know About Rxrx stock forecast.

gguy44. Recursion Pharmaceuticals ( NASDAQ: RXRX) is up 17% on Wednesday in much higher than usual volume as it may be in a short squeeze situation. As of 1215p ET, volume was ~16.6M shares ...5 equities research analysts have issued 12 month price objectives for Amneal Pharmaceuticals' stock. Their AMRX share price targets range from $3.00 to $7.00. On average, they expect the company's share price to reach $4.80 in the next twelve months. This suggests a possible upside of 9.8% from the stock's current price.Sep 20, 2022 · Zillow is worth $8.3 billion right now, so if it reaches its 2025 sales estimate and continues to grow thereafter, it should breeze past a $10 billion valuation by 2030. 2. Duolingo: Potential ... Nov 30, 2023 · Stock analysis for Recursion Pharmaceuticals Inc (RXRX:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

30 сент. 2023 г. ... NASDAQ: RXRX. Recursion Pharmaceuticals. Recursion Pharmaceuticals Stock Quote. Market Cap. $2B. Today's Change. (0.43%) $0.03. Current Price.

Jul 12, 2023 · For RXRX stock, which has suffered sharp losses against a long-term framework, AI may put the underlying company on the right track again. Still, investors need to be aware of separating the ... NVIDIA Corporation Common Stock. $416.10 +5.93 +1.45%. ARM. Arm Holdings plc American Depositary Shares. $51.32 -0.84 -1.61%. Find the latest analyst research for Recursion Pharmaceuticals, Inc ...

The average twelve-month price prediction for Recursion Pharmaceuticals is $11.20 with a high price target of $15.00 and a low price target of $8.00. Learn more on RXRX's analyst rating history. Do Wall Street analysts like Recursion Pharmaceuticals more than its competitors?Jul 13, 2023 · Over the past 3 months, 6 analysts have published their opinion on Recursion Pharmaceuticals (NASDAQ:RXRX) stock. These analysts are typically employed by large Wall Street banks and tasked with ... 60-Month Beta: Coefficient that measures the volatility of a stock's returns relative to the market (S&P 500). It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share.Analyst Price Forecast Suggests 117.07% Upside As of July 6, 2023, the average one-year price target for Recursion Pharmaceuticals Inc - is 14.72. The forecasts range from a low of 8.08 to a high ...

Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...

Always seek sound financial advice from your consultant or financial advisor before investing in the stock market. I am a grapefruit, and the stock market is a casino. Disclosure: No positions current in this stock, planning to go Long, likely for between 100 to 500 shares.

View the latest Recursion Pharmaceuticals Inc. (RXRX) stock price, news, historical charts, analyst ratings and financial information from WSJ.NASDAQ: RXRX Recursion Pharmaceuticals. Market Cap. $2B. Today's Change (7.88%) $0.54. Current Price. $7.39. ... Recursion's stock is up 73% this year, and while it doesn't have any recurring ...Insiders have purchased a total of 581,017 RXRX shares in the last 24 months for a total of $4,440,853.30 bought. Which Recursion Pharmaceuticals insiders have been selling company stock? The following insiders have sold RXRX shares in the last 24 months: Blake Borgeson ($2,846,394.44), Christopher Gibson ($14,439,192.59), …Get the latest Recursion Pharmaceuticals Inc (RXRX) real-time quote, historical performance, charts, and other financial information to help you make more informed …Find real-time RPRX - Royalty Pharma PLC stock quotes, company profile, news and forecasts from CNN Business.

For RXRX stock, which has suffered sharp losses against a long-term framework, AI may put the underlying company on the right track again. Still, investors need to be aware of separating the ...Both companies could tap into huge growth from the AI revolution in a few years. Schrödinger ( SDGR 2.90%) and Recursion Pharmaceuticals ( RXRX 4.40%) are both biotechs that want to use AI to ...What this means: Recursion Pharmaceuticals Inc Cl (RXRX) gets an Overall Rank of 60, which is an above average rank under InvestorsObserver's stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value.Recursion Pharmaceuticals (RXRX) stock price prediction is 10.137756245264 USD. The Recursion Pharmaceuticals stock forecast is 10.137756245264 USD for 2024 December 02, Monday; and 517.401 USD for 2028 December 02, Saturday with technical analysis.NVIDIA Corporation Common Stock. $416.10 +5.93 +1.45%. ARM. Arm Holdings plc American Depositary Shares. $51.32 -0.84 -1.61%. Find the latest analyst research for Recursion Pharmaceuticals, Inc ...30 сент. 2023 г. ... NASDAQ: RXRX. Recursion Pharmaceuticals. Recursion Pharmaceuticals Stock Quote. Market Cap. $2B. Today's Change. (0.43%) $0.03. Current Price.Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.

60-Month Beta: Coefficient that measures the volatility of a stock's returns relative to the market (S&P 500). It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share.

InvestorsObserver is giving Recursion Pharmaceuticals Inc (RXRX) an Analyst Rating Rank of 25, meaning RXRX is ranked higher by analysts than 25% of …Always seek sound financial advice from your consultant or financial advisor before investing in the stock market. I am a grapefruit, and the stock market is a casino. Disclosure: No positions current in this stock, planning to go Long, likely for between 100 to 500 shares.Find the latest news headlines from Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.That’s as shares of Recursion Pharmaceuticals RXRX are exploding higher on the day. In fact, RXRX stock is currently up about 17% so far in the session. Butterfly with parabolic D leg action. This looks like classic D leg stuff. All parabolic action, few pullbacks and getting a lot of public attention. Complete Recursion Pharmaceuticals Inc. stock information by Barron's. View real-time RXRX stock price and news, along with industry-best analysis.Get the latest stock price for Recursion Pharmaceuticals Inc. (RXRX:US), plus the latest news, recent trades, charting, insider activity, ...Track Recursion Pharmaceuticals Inc - Ordinary Shares - Class A (RXRX) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors

What this means: Recursion Pharmaceuticals Inc Cl (RXRX) gets an Overall Rank of 60, which is an above average rank under InvestorsObserver's stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value.

(See RXRX stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy , a newly launched tool that unites all of TipRanks’ equity insights.

For RXRX stock, which has suffered sharp losses against a long-term framework, AI may put the underlying company on the right track again. Still, investors need to be aware of separating the ...Average. $15.57. Current Price. $7.39. Options. Overview. Research & Ratings. Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume ...2013. 550. Chris Gibson. https://www.recursion.com. Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which ...Historical daily share price chart and data for Recursion Pharmaceuticals since 2021 adjusted for splits and dividends. The latest closing stock price for ...Earnings for Recursion Pharmaceuticals are expected to decrease in the coming year, from ($1.67) to ($1.91) per share. Recursion Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, February 26th, 2024 based off prior year's report dates. Read More.47.29. According to our current RXRX stock forecast, the value of Recursion Pharmaceuticals, Inc. shares will rise by 7.47% and reach $ 7.37 per share by December 2, 2023. According to our technical indicators, the current sentiment is Neutral while the Fear & Greed Index is showing 39 (Fear). RXRX stock recorded 13/30 (43%) green days with 9. ... Average. $15.57. Current Price. $7.39. Options. Overview. Research & Ratings. Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume ...Nowadays finding high-quality stock photos for personal or commercial use is very simple. You just need to search the photo using a few descriptive words and let Google do the rest of the work.RXRX has an Altman Z-Score of 1.55 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy. Detailed statistics for Recursion Pharmaceuticals, Inc. (RXRX) stock, including valuation metrics, financial numbers, share information and more.RXRX stock does seem to be getting support at the 200-day moving average, at least for now. Wood also trimmed her holdings of Shopify in her flagship ARK Innovation ETF by just over 182,000 shares ...Find the latest Insider Activity data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.

Jul 21, 2023 · NASDAQ: RXRX Recursion Pharmaceuticals. Market Cap. $2B. Today's Change (7.88%) $0.54. Current Price. $7.39. ... Recursion's stock is up 73% this year, and while it doesn't have any recurring ... Price/Earnings Ratio is a widely used stock evaluation measure. For a security, the Price/Earnings Ratio is given by dividing the Last Sale Price by the Actual EPS (Earnings Per Share). data ...Jul 21, 2023 · NASDAQ: RXRX Recursion Pharmaceuticals. Market Cap. $2B. Today's Change (7.88%) $0.54. Current Price. $7.39. ... Recursion's stock is up 73% this year, and while it doesn't have any recurring ... Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) shareholders will have a reason to smile today, with the analysts making substantial upgrades to next year's forecasts.The consensus statutory numbers ...Instagram:https://instagram. congress etftop fha lendersinvestors hangout rmhbwwe srock July 12 (Reuters) - Chip designer Nvidia (NVDA.O) will invest $50 million to speed up training of Recursion's (RXRX.O) artificial intelligence models for drug discovery, the companies said on ... mo dividendsbest tax free bonds RXRX has a market cap of $1.73bn and a cash balance of $454mn. Research and development expenses were $40.8 million for the third quarter of 2022, while general and administrative expenses were ...As of July 24, 2023, 4:00 PM CST, Recursion Pharmaceuticals Inc’s stock price was $14.28. Recursion Pharmaceuticals Inc is down 7.69% from its previous closing price of $15.47. During the last market session, Recursion Pharmaceuticals Inc’s stock traded between $14.36 and $16.09. 1921 1 dollar coin value Recursion Pharmaceuticals Stock Prediction. BSX. 63Recursion Pharma may be a biotech stock, but it scored a $50 million investment from Nvidia to fund its AI technology in mid-July - making NVDA a significant stakeholder in RXRX.